Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
US FDA Approves Myrbetriq/Vesicare Combination Therapy for OAB: Astellas
Astellas Pharma announced on May 8 that the US FDA has approved mirabegron (brand name: Myrbetriq) in combination with solifenacin (Vesicare) for the treatment of overactive bladder (OAB).The combination use was approved for the treatment of OAB with symptoms of…
To read the full story
Related Article
- FDA Accepts sNDA for Mirabegron Combo Therapy: Astellas
September 14, 2017
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…